A recent study from the Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts; Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA; and Institute for Biomedical Research, University College London, London, UK shows that “Nociceptive sensory neurons drive interleukin-23-mediated psoriasiform skin inflammation.” This study was published in the Apr 23 2014 Nature by Prof Ulrich H. von Andrian, Lorena Riol-Blanco, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Vitamins-based therapy for Psoriasis: 1α,25-dihydroxyvitamin D(3) inhibits psoriasiform skin inflammation via up regulation of its target gene. This study suggests that 1α,25-dihydroxyvitamin D(3), by increasing the expression of its target gene, it may alleviate the interleukin-23-mediated psoriasiform skin inflammation. Together, this study suggests that pharmacological formulations encompassing “1α,25-dihydroxyvitamin D(3) or its analogues” may be used to treat psoriasiform skin inflammation.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, L., Vitamins-based therapy for Psoriasis: 1α,25-dihydroxyvitamin D(3) inhibits psoriasiform skin inflammation via up regulation of its target gene, 31/July/2014, 5.36 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org
* Research cooperation